We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quidel Receives CE Mark for its First Molecular Diagnostic Test
Product News

Quidel Receives CE Mark for its First Molecular Diagnostic Test

Quidel Receives CE Mark for its First Molecular Diagnostic Test
Product News

Quidel Receives CE Mark for its First Molecular Diagnostic Test


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Quidel Receives CE Mark for its First Molecular Diagnostic Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Quidel Corporation, has announced that it has received the CE Mark for the Quidel® Molecular Influenza A+B Real-Time RT-PCR Assay - its first molecular diagnostic test.

This is the first of several forthcoming Quidel Molecular Real-Time PCR Assays that provide important benefits to the customer, including, among others, room temperature storage, reduced process time, and ready-to-use reagent configurations.

The CE mark clears the way for the launch of the open box molecular platform well in advance of the forthcoming influenza season in Europe, while also facilitating the launch of the product in other ex-U.S. locations. The product is not for sale in the U.S. at this time.

"Completing the development of our Quidel Molecular Influenza A+B Real-Time RT-PCR Assay is just the beginning of a new and very exciting time for our company," said Douglas Bryant, president and chief executive officer of Quidel Corporation.

"Our molecular diagnostic program is proceeding on schedule and shows great promise for the coming year."

Advertisement